ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

3-メチル-1-フェニル-5-ピラゾロン

Mci-186

HCID 4021
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
89-25-8
標準SMILES
CC1=NN(c2ccccc2)C(=O)C1
InChIKey
QELUYTUMUWHWMC-UHFFFAOYSA-N
分子式
C10H10N2O
平均分子量
174.2 g/mol
単同位体質量
174.07931295

概要

1-phenyl-3-methyl-5-pyrazolone appears as white to off-white powder or crystals. (NTP, 1992)

名称と識別子

優先名称
Mci-186
IUPAC
5-methyl-2-phenyl-4H-pyrazol-3-one
現地名
3-メチル-1-フェニル-5-ピラゾロン
英語名
5-Methyl-2-phenyl-1,2-dihydropyrazol-3-one
分子式
C10H10N2O
分子量
174.2

名称と別名

MCI-186MCI 186RefChem:57584edaravone89-25-83-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONENorphenazoneRadicut1-Phenyl-3-methyl-5-pyrazoloneDeveloper ZMethylphenylpyrazoloneNorantipyrine
名称をさらに表示
3-メチル-1-フェニル-5-ピラゾロン1-フェニル-3-メチル-4,5-ジヒドロ-1H-ピラゾール-5-オン1-フェニル-3-メチル-1H-ピラゾール-5(4H)-オン3-メチル-1-フェニル-5(4H)-ピラゾロンメフェラベンラジカット5-メチル-2-フェニル-2,4-ジヒドロ-3H-ピラゾール-3-オン3-メチル-1-フェニル-1H-ピラゾール-5(4H)-オン1-フェニル-3-メチル-5(4H)-ピラゾロン3-メチル-1-フェニル-2-ピラゾリン-5-オン1-フェニル-3-メチル-2-ピラゾリン-5-オン1-フェニル-3-メチル-1,4-ジヒドロ-5H-ピラゾール-5-オンC.I.デベロッパー1デベロッパーZエダラボン2-フェニル-5-メチル-2H-ピラゾール-3(4H)-オンノルフェナゾン2-フェニル-5-メチル-2,4-ジヒドロ-3H-ピラゾール-3-オン1-(フェニル)-3-メチル-2-ピラゾリン-5-オンノルアンチピリンPMPMONOPYRAZOLONEPHENYLMETHYLPYRAZOLON
PhenylmethylpyrazoloneC.I. Developer 1RadicavaPhenyl methyl pyrazolone3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one3-Methyl-1-phenyl-5-pyrazolone5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one5-methyl-2-phenyl-4H-pyrazol-3-one

データベース識別子

CAS
89-25-8
PubChem CID
4021
DTXSID
DTXSID9021130
ChEMBL
CHEMBL290916
ChEBI
CHEBI:31530
UNII
S798V6YJRP
EC Number
201-891-0
Nikkaji
J37.341I

物性

構造計算による物性

XLogP
1.3
極性表面積
32.7 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
1
重原子数
13
形式電荷
0
複雑度
241

実験および物理化学的性質

Chemical ClassesNitrogen Compounds -> Pyrazoles
DrugsPharmaceuticals -> Listed in ZINC15
Cosmetics · 2 件

Cosmetic ingredients (Phenyl Methyl Pyrazolone) -> CIR (Cosmetic Ingredient Review)

Hair dyeing

LogP1.44
Color/Form · 2 件

MONOCLINIC PRISMS FROM WATER

WHITE POWDER OR CRYSTALS

Solubility · 3 件

less than 1 mg/mL at 73 °F (NTP, 1992)

SOL IN HOT WATER & HOT ALCOHOL; SLIGHTLY SOL IN BENZENE; INSOL IN PETROLEUM ETHER

25.4 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Boiling Point · 2 件

549 °F at 105 mmHg (NTP, 1992)

191 °C @ 17 MM HG; 287 °C @ 105 MM HG

Melting Point · 3 件

261 to 266 °F (NTP, 1992)

127 °C

128.9 °C

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

This chemical does not meet GHS hazard criteria for 7.7% (16 of 209) of reports.

Warning

H302 (26.8%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 209 reports by companies from 25 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

危険有害性情報

Regulatory Information · 3 件

Chemical: 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-

REACH registered substance: 3-methyl-1-phenyl-5-pyrazolone (EC: 201-891-0)

3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-: Human health tier II assessment
Fire HazardsFlash point data for this chemical are not available. It is probably combustible. (NTP, 1992)
Health HazardsSYMPTOMS: Symptoms of exposure to this compound may include irritation of the skin, eyes and mucous membranes.
Hazards Summary · 1 件

Emergency treatment: Irritants; [HSDB] A skin, eye, and mucous membrane irritant; [CAMEO] Causes no to mild skin and eye irritation in rabbits; Not sensitizing to guinea pig skin; [IUCLID] No teratogenicity observed in experimental animals, but reduced birth weight and fetal loss seen at high doses; [REPROTOX] No evidence for carcinogenicity in mice or rats; [NTP] A mild eye irritant; Causes changes in liver and spleen in intravenous studies of dogs; [RTECS]

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein BindingEdaravone is 92% bound to human serum proteins, mainly to albumin, with no concentration dependence in the range of 0.1 to 50 micromol/L.
PharmacodynamicsEdaravone works to delay the disease progression of neurological disorders such as ischemic stroke and ALS by limiting the extent of neuronal damage or death.
Mechanism of Action · 1 件

Oxidative stress and reactive oxygen species (ROS) production have been implicated in various neurological disorders, such as amyotrophic lateral sclerosis (ALS) and cerebral ischemia. Oxidative stress caused by excess ROS damages endothelial cells in the cerebral vasculature as well as neuronal cell membranes, leading to neuronal cell death. Edaravone is a free radical scavenger that scavenges and suppresses the generation of hydroxyl radicals and peroxynitrite radicals. The exact mechanism of action of edaravone in ALS has not been fully elucidated; however, edaravone is thought to mediate therapeutic effects via its antioxidant properties. Since oxidative stress has been implicated in the pathophysiology of ALS and cerebral ischemia, inhibiting lipid peroxidation, suppressing endothelial cell damage induced by lipid peroxides, and scavenging free radicals may lead to neuroprotective effects. Edaravone has no effect on superoxide production. It is suggested that edaravone may also possess anti-inflammatory properties, as it inhibited neutrophil activation and suppressed inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS) expression in animal models. It was also shown to ameliorate ROS-induced inflammatory oxidative stress after ischemic brain reperfusion.

Biological Half-LifeThe mean terminal elimination half-life of edaravone is approximately 4.5 to nine hours. The half-lives of its metabolites range from three to six hours.
Metabolism/Metabolites · 1 件

The metabolites of edaravone have not been fully characterized. Edaravone is metabolized to a sulfate conjugate and a glucuronide conjugate, which are not pharmacologically active. The glucuronide conjugation of edaravone involves multiple uridine diphosphate glucuronosyltransferase (UGT) isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B17). In human plasma, edaravone is mainly detected as the sulfate conjugate, which is presumed to be formed by sulfotransferases. Oral edaravone results in 1.3- and 1.7-fold higher exposures for both sulfate and glucuronide metabolites, respectively, when compared to intravenously-administered edaravone because of first-pass metabolism.

関連反応

21 件
反応記録を作成
HRID 105365 の反応式
HRID 105365反応物として
HRID 293402 の反応式
HRID 293402反応物として
HRID 302741 の反応式
HRID 302741反応物として
HRID 315839 の反応式
HRID 315839反応物として
HRID 362451 の反応式
HRID 362451反応物として
HRID 382796 の反応式
HRID 382796反応物として
HRID 531189 の反応式
HRID 531189反応物として
HRID 950576 の反応式
HRID 950576反応物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Vapor Pressure · 2 件

less than 0.01 mmHg at 68 °F (NTP, 1992)

LESS THAN 0.01 MM @ 20 °C

Refractive IndexMAX ABSORPTION (ALCOHOL): 280 NM SHOULDER (LOG E= 3.6) INDEX OF REFRACTION: 1.637; MAX ABSORPTION (ALCOHOL): 245 NM (LOG E= 1.1)
Physical Description · 2 件

1-phenyl-3-methyl-5-pyrazolone appears as white to off-white powder or crystals. (NTP, 1992)

White solid; [Merck Index] Light yellow odorless powder; [Alfa Aesar MSDS]

物理化学的性質

融点
126 · 126-128 °C(lit.)
沸点
287 °C265 · 287 °C265 mm Hg(lit.)
比重(密度)
1 · 1,12 g/cm3
蒸気圧
0.016 Pa · 0.016Pa at 20℃
屈折率
1.63 · 1.6300 (estimate)
闪点
191 °C/17mm · 191°C/17mm
貯蔵温度
2 · 2-8°C
溶解性
3.3 g/リットル · 3.30g/リットル
酸解離定数(Pka)
2.73 · 2.73±0.50(Predicted)
外見
結晶性粉末
色
黄色からベージュ
PH
4 · 4.0-4.4 (H2O, 20℃)(saturated aqueous solution)
水溶解度
3 g/L · 3g/L(20℃)
Merck
14 · 14,6713
BRN
609575 · 609575
安定性
-20 °Cで最大3か月保存できます。 · DMSO溶液またはエタノール溶液で-20°Cで最大3か月保存できます。
主な用途
ペプチド合成
化粧品成分の機能
ヘアカラーリング
InChI
1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
InChIKey
QELUYTUMUWHWMC-UHFFFAOYSA-N
SMILES
CC1=NN(C(=O)C1)c2ccccc2
LogP
0.75 at · 0.75 at 24℃
CAS データベース
89 · 89-25-8(CAS DataBase Reference)
NISTの化学物質情報
3 H-Pyrazol-3-one, · 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-(89-25-8)
EPAの化学物質情報
1 · 1-Phenyl-3-methyl-5-pyrazolone (89-25-8)

化学的性質

化学的特性Off white to light yellow powder

Reactive GroupAmides and Imides
Special ReportsDHEW/NCI; Bioassay of 1-Phenyl-3-methyl-5-pyrazolone for Possible Carcinogenicity (1978) Technical Rpt Series No. 141 DHEW Pub No. (NIH) 78-1396
Reactivity Profile · 1 件

Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.

Air and Water ReactionsInsoluble in water.
Hazard Classes and Categories · 2 件

Acute Tox. 4 (26.8%)

Skin sensitisation - category 1

安全と保護具

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 件

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 件

SMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with ethanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Protective Action Criteria (PAC) · 3 件

5.7 [mg/m3]

63 [mg/m3]

380 [mg/m3]

Personal Protective Equipment (PPE) · 1 件

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

毒性情報

Hepatotoxicity · 1 件

Serum aminotransferase elevations occur in a small proportion of patients on edaravone therapy, but the frequency, timing of onset, duration and severity of these elevations has not been defined. The rates of abnormal liver tests during edaravone therapy were said to be similar to those during placebo treatment. Most elevations resolved spontaneously, and there were no reports of drug discontinuation for serum enzyme elevations. Clinically apparent liver injury due to edaravone was not reported in the prelicensure trials and has not been reported with subsequent clinical use of edaravone, but the numbers of patients treated have been few. Thus, clinically apparent liver injury from edaravone must be rare if it occurs at all.

Toxicity SummarySafe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org
Ongoing Test Status · 1 件

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=89-25-8]

Carcinogen Classification · 6 件

1-Phenyl-3-methyl-5-pyrazolone

TR-141: Bioassay of 1-Phenyl-3-methyl-5-pyrazolone for Possible Carcinogenicity (CASRN 89-25-8) (1978 )

06/29/78

No Evidence

No Evidence

No Evidence

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Edaravone

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts... Levels of Evidence of Carcinogenicity: Male Rats: Negative; Female Rats: Negative; Male Mice: Negative; Female Mice: Negative.
National Toxicology Program Studies · 1 件

A bioassay of 1-phenyl-3-methyl-5-pyrazolone for possible carcinogenicity was conducted using Fischer 344 rats and B6C3Fl mice. l-Phenyl-3-methyl-5-pyrazolone was admin in the feed, at either of two concn, to groups of 49 or 50 male and 50 female animals of each species. The high and low concn of 1-phenyl-3-methyl-5-pyrazolone utilized were, respectively, 5,000 and 2,500 ppm for rats and 15,000 and 7,500 ppm for mice. Twenty animals of each species and sex were placed on test as controls. After a 103 wk period of chemical admin, there was an additional observation period of 2 wk for rats. A 102 wk period of chemical admin was followed by an additional 2 wk observation period for mice. In both species adequate numbers of animals survived sufficiently long to be at risk from late developing tumors. ... Under the conditions of this bioassay, there was no evidence for the carcinogenicity of 1-phenyl-3-methyl-5-pyrazolone to Fischer 344 rats or B6C3Fl mice. ... Levels of Evidence of Carcinogenicity: Male Rats: Negative; Female Rats: Negative; Male Mice: Negative; Female Mice: Negative.

安全データ

wgk
1
tsca
TSCA listed
rtecs
UQ9625000
毒性
LD50 orl-rat: 3500 mg/kg LONZA# 08FEB79
hs_code
2933199090
risk_code
36/37/38
化審法
(5)-287
hazard_code
Xi
safety_code
26-36
Hazard Classifications
Acute Tox. 4 OralEye Irrit. 2
ストレージクラス
11 - Combustible Solids
有毒物質データの
89-25-8(Hazardous Substances Data)
MeSH Pharmacological Classification · 2 件

Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY.

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Absorption, Distribution and Excretion · 4 件

One study investigated the absorption of edaravone in healthy adults, who either received a single oral (105 mg/mL) or intravenous (60 mg/60 min) dose. The mean Cmax (CV%) and Tmax were 1656 (44.3) ng/mL and 0.5 hours, respectively, following oral administration. The absolute oral bioavailability is about 57% because of first-pass metabolism. The mean Cmax (CV%) and Tmax were 1253 (18.3) ng/mL and one hour, respectively, following intravenous administration. When intravenously administered, the maximum plasma concentration (Cmax) of edaravone was reached by the end of infusion. The Cmax and area under the concentration-time curve (AUC) of edaravone increases more than dose-proportional over the dose range of 30 to 300 mg. Edaravone does not accumulate in plasma with once-daily or multiple-dose administration. The Cmax and AUC decreased when the oral suspension formulation of edaravone was administered with a high-fat meal.

In Japanese and Caucasian healthy volunteer studies, edaravone was excreted mainly in the urine as its glucuronide conjugate (60-80% of the dose up to 48 hours). Approximately 6-8% of the dose was recovered in the urine as the sulfate conjugate, and <1% of the dose was recovered in the urine as the unchanged drug. _In vitro_ studies suggest that the sulfate conjugate of edaravone is hydrolyzed back to edaravone, which is then converted to the glucuronide conjugate in the kidney before excretion into the urine.

After intravenous administration, edaravone has a mean volume of distribution of 63.1 L, suggesting substantial tissue distribution. Edaravone has an apparent volume of distribution of 164 L following oral administration. Edaravone readily crosses the blood-brain barrier.

Following intravenous administration, the total clearance of edaravone is estimated to be 35.9 L/h. The apparent total clearance of edaravone is estimated to be 67.9L/h following oral administration.

用途と製造

Uses · 5 件

CIR ingredient: Phenyl Methyl Pyrazolone

Used as an intermediate for dyes and drugs, reagent to detect cyanide, and developer for diazotized direct dyes; [HSDB] Used in the treatment of strokes; [Merck Index] Used for synthesis in the chemical industry and in the textile processing industry; [IUCLID] Used in hair dyes; [ExPub: EC]

Textiles (Printing, Dyeing, or Finishing) [Category: Industry]

INTERMEDIATE FOR DYES & DRUGS; SENSITIVE REAGENT FOR DETECTION OF CYANIDE

CHEM INT FOR DYES (EG, FOR PYRAZOLONE PIGMENTS), DRUGS (EG, ANTIPYRINE & AMINOPYRINE), DEVELOPER FOR DIAZOTISED DIRECT DYES, REAGENT FOR DETECTION OF CYANIDE

U.S. Exports · 2 件

(1977) No Data

(1979) No Data

U.S. Imports · 2 件

(1977) 6.01X10+7 GRAMS (PRINCPL CUSTMS DISTS)

(1979) 1.55X10+8 GRAMS (PRINCPL CUSTMS DISTS)

U.S. Production · 2 件

(1976) 5.90X10+6 GRAMS (SALES)

(1979) PROBABLY GREATER THAN 2.27X10+6 GRAMS

Methods of Manufacturing · 2 件

CONDENSATION OF PHENYLHYDRAZINE WITH ETHYL ACETOACETATE

BY CONDENSATION OF PHENYLHYDRAZINE WITH ETHYLACETOACETATE.

Household ProductsInformation on 99 consumer products that contain Phenyl methyl pyrazolone in the following categories is provided:
Use ClassificationCosmetics -> Hair dyeing
General Manufacturing Information3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-: ACTIVE
応用分野 · 4 件

用途アンチピリン、アミノピリンをはじめ、多くの重要な医薬品あるいは染料の原料となる。

説明Edaravone was marketed in Japan for improving neurologic recovery following acute brain infarction. Currently, several agents classified as neuroprotectants and acting by diverse mechanisms (inhibition of glutamate release, blockade of calcium channels, lazaroids) have been marketed for treating the outcomes of brain damage due to trauma, ischemia or cardiac arrest. Edavarone is the first antioxidant with free radical scavenging activity to be introduced for this pathology. This previously described molecule (in particular as norantipyrine, one of three metabolites of antipyrine in mammals) can be simply prepared by direct cyclization of phenylhydrazine with alkylacetoacetate. Edarevone is a lipophilic agent, readily accessible to brain tissue, that is capable of reducing edema in the brain following ischemia by blocking the arachidonic acid cascade triggering peroxidative neurodegeneration. Interestingly, this agent has been shown to quench active oxygen species in endothelial cell homogenate, as well as inhibiting in vitro lipid peroxidative disintegration of membranes, so making this compound effective during reperfusion following ischemic injury. As an additional indication, phase III trials started with edaravone for increasing the chance of recovery after subarachnoid hemorrhage.

使用Edaravone inhibits the disease activity in rheumatoid arthritis.

一般的な説明A free radical scavenger and antioxidant that reduces post-ischemic brain injury. Inhibits iron-dependent peroxidation in rat brain homogenates (IC50 = 15 μM). Inhibits mitochondrial permeability transition pore.

調製方法

純化方法Crystallise the pyrazolone from hot H2O, EtOH or EtOH/water (1:1). It complexes with metals. [Veibel et al. Acta Chim Scand 6 1066 1952, Beilstein 24 II 9, 24 III/IV 71.]

上流・下流製品情報

上流原料

ジケテン亜硝酸アンモニウム3-オキソブチルアミドアンモニア水エタノール2-(アセチルオキシ)酢酸亜硫酸水素アンモニウムホルマリンぎ酸亜硝酸ナトリウムアニリン塩酸p-トルイジンメタン硫酸水素炭酸ナトリウムアンモニア二亜硫酸二ナトリウムジメチル硫酸

下流製品

キシレン ファスト イエロー 2Gsodium [2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)][1-[(2-hydroxy-4-nitrophenyl)azo]-2-naphtholato(2-)]cobaltate(1-)Neutral Bordeaux D-BNTracid Light Yellow G1,2-ジメチル-3,5-ジフェニル-1H-ピラゾール-2-イウム·(硫酸メチル)イオンエリオクロムレッドBピラゾール3,5-ジフェニル-1H-ピラゾールCuprate(2-), [4-[bis[4-(diethylamino)phenyl]hydroxymethyl]-5-[(4,5-dihydro-3-methyl-5-(oxo-κO)-1-phenyl-1H-pyrazol-4-yl)azo-κN1]-6-(hydroxy-κO)-1,3-benzenedisulfonato(4-)]-, disodium

補足説明

定義ChEBI: A pyrazolone that is 2,4-dihydro-3H-pyrazol-3-one which is substituted at positions 2 and 5 by phenyl and methyl groups, respectively.